PMID- 16902319
OWN - NLM
STAT- MEDLINE
DCOM- 20061211
LR  - 20170118
IS  - 1660-2129 (Electronic)
IS  - 1660-2129 (Linking)
VI  - 104
IP  - 4
DP  - 2006
TI  - Renoprotective effect of breviscapine through suppression of renal macrophage 
      recruitment in streptozotocin-induced diabetic rats.
PG  - e147-57
AB  - BACKGROUND/AIMS: Experimental and clinical evidence has consistently demonstrated 
      that renal macrophage infiltration is one of the most important events for the 
      progression of diabetic nephropathy. Breviscapine is a flavonoid extracted from 
      the Chinese herb Erigeron breviscapus. Previously, it was shown that treatment 
      with breviscapine attenuated renal injury in the diabetic rats. The purpose of 
      this study is to investigate whether the renoprotective effect of breviscapine is 
      through suppression of renal macrophage recruitment in diabetic rats. METHODS: 
      Diabetes was induced bystreptozotocin injection, and breviscapine was 
      administered orally at a dose of 20 mg/kg/day for 8 weeks. Control rats received 
      vehicle or breviscapine with the same schedule. RESULTS: Breviscapine treatment 
      markedly inhibited both an increase of albuminuria and glomeruli hypertrophy and 
      tubulointerstitial injury without modifying mean arterial blood pressure and 
      creatinine clearance. Levels of malondialdehyde and protein kinase C activities 
      were markedly higher and antioxidant enzyme activities such as superoxide 
      dismutase, catalase as well as glutathione peroxidase were significantly lower in 
      the kidneys of diabetic rats than of the control group, breviscapine 
      administration markedly remitted these changes. ED-1-positive cells and 
      expression of intercellular adhesion molecule-1 (ICAM-1) and monocyte 
      chemoattractant protein-1 (MCP-1) in glomeruli and tubulointerstitium were all 
      markedly elevated but were significantly reduced by breviscapine. Western blot 
      analysis noted that the expression of transforming growth factor beta1 protein 
      was increased 1.8-fold in the kidney in diabetic rats, breviscapine treatment 
      could reduce increased expression of TGF-beta1 protein by 47%. CONCLUSION: This 
      study describes a novel mechanism by which breviscapine confers a renoprotective 
      effect.
CI  - Copyright 2006 S. Karger AG, Basel.
FAU - Qi, Xiang Ming
AU  - Qi XM
AD  - Department of Nephropathy, The First Affiliated Hospital of AnHui Medical 
      University, Hefei, PR China.
FAU - Wu, Guo Zhong
AU  - Wu GZ
FAU - Wu, Yong Gui
AU  - Wu YG
FAU - Lin, Hui
AU  - Lin H
FAU - Shen, Ji Jia
AU  - Shen JJ
FAU - Lin, Shan Yan
AU  - Lin SY
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20060810
PL  - Switzerland
TA  - Nephron Exp Nephrol
JT  - Nephron. Experimental nephrology
JID - 101159770
RN  - 0 (Chemokine CCL2)
RN  - 0 (Flavonoids)
RN  - 116122-36-2 (breviscapine)
RN  - 126547-89-5 (Intercellular Adhesion Molecule-1)
SB  - IM
MH  - Animals
MH  - Chemokine CCL2/analysis
MH  - Diabetes Mellitus, Experimental/drug therapy/*physiopathology
MH  - Diabetic Nephropathies/prevention & control
MH  - Flavonoids/*pharmacology
MH  - Intercellular Adhesion Molecule-1/analysis
MH  - Kidney Glomerulus/drug effects/pathology
MH  - Macrophages/*drug effects
MH  - Male
MH  - Oxidative Stress/drug effects
MH  - Rats
EDAT- 2006/08/12 09:00
MHDA- 2006/12/12 09:00
CRDT- 2006/08/12 09:00
PHST- 2005/08/18 00:00 [received]
PHST- 2006/02/21 00:00 [accepted]
PHST- 2006/08/12 09:00 [pubmed]
PHST- 2006/12/12 09:00 [medline]
PHST- 2006/08/12 09:00 [entrez]
AID - 94966 [pii]
AID - 10.1159/000094966 [doi]
PST - ppublish
SO  - Nephron Exp Nephrol. 2006;104(4):e147-57. doi: 10.1159/000094966. Epub 2006 Aug 
      10.